|
Lesofat® Manufacturer: Dr Zens ResearchClass: Anti-obesity Agents |
 |
 | |
| Contents | Orlistat |
| Indications | In conjunction with dietary modification in the management of obesity i.e. in patients with BMI ≥25 kg/m2. Also, in patients with BMI ≥23 kg/m2 if there are associated risk factors e.g. hypercholesterolemia, HTN and cardiovascular diseases. |
| Dosage | 1 cap tid. |
| Administration | Should be taken with food (Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.). |
| Contraindications | If taking cyclosporine. Chronic malabsorption syndrome or cholestasis; gallbladder problems; undergone organ transplant; allergic reaction w/ orlistat. |
| Special Precautions | Diabetic patients. Fat-soluble vit may be necessary during long-term therapy, but should be taken at least 2 hr before or after an orlistat dose or at bed time. Pregnancy & lactation. Childn <18 yr. |
| Adverse Drug Reactions | GI disturbances eg fecal incontinence, flatulence, fatty stools or discharge. |
| Pregnancy Category (US FDA) | Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
| ATC Classification | A08AB01 - Orlistat ; Belongs to the class of peripherally acting antiobesity products. Used in the treatment of obesity. |
| Poison Schedule | Non-Rx |
PACKING / PRESENTATION
| Form | Packing/Price |
| Capsule | 120 mg x 30's (P39.75/cap) |